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Key questions
What is already known about this subject?
 ► Atrial fibrillation (AF) is a major risk factor for 
strokes that can be prevented via oral anticoagula-
tion (OAC). Opportunistic, symptom-based, and sin-
gle time-point diagnostic tests have limited yields. 
Continuous monitoring with an insertable cardiac 
monitor (ICM) in the REVEAL AF study demonstrated 
a high incidence of AF in high-risk patients where 
previous external monitoring (≥24 hours) was nega-
tive. The cost-effectiveness of ICM monitoring in this 
population is unknown.
What does this study add?
 ► In a population with mean CHADS2 score of 2.94, 
the cost per quality-adjusted life-year gained with 
ICM compared with Standard of Care (SoC) was 
£7140, a value well below conventional thresholds 
for cost-effectiveness. Results were sensitive to the 
cost of SoC and to rates of uptake and duration of 
OAC therapy after diagnosis.
How might this impact on clinical practice?
 ► The use of ICMs to detect AF and identify high-risk 
candidates for OAC improves health outcomes rel-
ative to SoC at an acceptable extra cost to the UK 
National Health Service.
AbstrAct
Objective To evaluate the cost-effectiveness of insertable 
cardiac monitors (ICMs) compared with standard of care 
(SoC) for detecting atrial fibrillation (AF) in patients at high 
risk of stroke (CHADS
2 >2), using a UK National Health 
Service (NHS) perspective.
Methods Using patient characteristics and clinical data 
from the REVEAL AF trial, a Markov model assessed the 
cost-effectiveness of detecting AF with an ICM compared 
with SoC. Costs and benefits were extrapolated across 
modelled patient lifetime. Ischaemic and haemorrhagic 
strokes, intracranial and extracranial haemorrhages and 
minor bleeds were modelled. Diagnostic and device costs 
were included, plus costs of treating stroke and bleeding 
events and costs of oral anticoagulants (OACs). Costs and 
health outcomes, measured as quality-adjusted life years 
(QALYs), were discounted at 3.5% per annum. One-way 
deterministic and probabilistic sensitivity analyses (PSA) 
were undertaken.
Results The total per-patient cost for ICM was £13 360 
versus £11 936 for SoC (namely, annual 24 hours Holter 
monitoring). ICMs generated a total of 6.50 QALYs versus 
6.30 for SoC. The incremental cost-effectiveness ratio 
(ICER) was £7140/QALY gained, below the £20 000/QALY 
acceptability threshold. ICMs were cost-effective in 77.4% 
of PSA simulations. The number of ICMs needed to prevent 
one stroke was 21 and to cause a major bleed was 37. 
ICERs were sensitive to assumed proportions of patients 
initiating or discontinuing OAC after AF diagnosis, type of 
OAC used and how intense the traditional monitoring was 
assumed to be under SoC.
Conclusions The use of ICMs to identify AF in a high-risk 
population is cost-effective for the UK NHS.
IntROduCtIOn
Atrial fibrillation (AF) has long been associ-
ated with stroke risk.1 2 Although anticoagu-
lation therapy can effectively reduce stroke 
risk in patients with AF, initial diagnosis can 
be challenging. Symptoms may be non-spe-
cific, AF may be intermittent3 and current 
opportunistic short-term monitoring solu-
tions (such as wearing a Holter monitor for 
24 hours) are not well suited to detect all AF 
episodes. Further, correlation of even specific 
symptoms and a pathological underlying 
rhythm can be difficult.4
Insertable cardiac monitors (ICMs) can 
continuously monitor patients for AF. The 
REVEAL AF study5 used Reveal® (Medtronic, 
Dublin, Ireland) ICM devices to detect AF. 
The study patients had non-specific symp-
toms, sufficient stroke risk factors to require 
oral anticoagulation (OAC) therapy should 
AF be detected and no AF found following 
at least 24 hours of external monitoring 
performed within 90 days prior to study 
enrolment. After 18 months, the AF detec-
tion rate for episodes lasting at least 6 min 
was found to be 29.3%; at 30 months, the rate 
was 39.8%.
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ICM use in this patient population is clinically effective 
in diagnosing previously undetected AF but its cost-effec-
tiveness compared with standard care (SoC) in this appli-
cation is unknown.
MetHOds
A Markov model was created to compare costs and bene-
fits of Reveal® ICM versus SoC in patients with high risk 
of stroke but no confirmed AF diagnosis. Based on a 
similar analysis in cryptogenic stroke,6 the model esti-
mated monitoring and treatment costs from a UK NHS 
perspective, and health benefits as quality-adjusted life 
years (QALYs), discounted at 3.5% annually.7 The model 
allowed estimation of life-years gained and stroke events 
avoided. The model cohort was set up to have the same 
baseline characteristics as recorded in the REVEAL AF 
clinical trial5 ( Clinicaltrials. gov, NCT01727297) (see 
online supplementary file 1).
A lifetime horizon captured all relevant costs and 
health-related quality of life (QoL) effects. Cycle length 
for recording outcomes was 3 months, matching follow-up 
intervals in the REVEAL AF trial.
Model structure
The model estimates both the efficacy and costs of the 
ICM device itself as well as the potential costs and health 
effects of timely and accurate diagnosis.
In the model’s hypothetical cohort, all patients with 
underlying AF are assumed to be undiagnosed at base-
line. In each cycle, patients with AF may remain undi-
agnosed, have existing AF detected, or, for patients with 
no underlying AF initially, develop AF. Patients in whom 
AF is detected are assumed to receive new OAC (NOAC) 
therapy (non-vitamin-K OAC); by contrast, patients with 
undetected AF will have no change in their treatment. 
Thus, patients with undetected AF are assumed not to 
receive anticoagulation for stroke prevention. Patients 
who have a stroke will subsequently move to a post-stroke 
health state, where they are assumed to remain. AF detec-
tion status and treatment received can still change in 
these states, but patients cannot transit to other states 
except death.
Movement of patients through the model is shown in 
figure 1.
Input parameters
Population
The patient cohort reflects the baseline characteristics of 
the REVEAL AF trial population, with 72.6% receiving 
aspirin treatment and 20.3% having a history of stroke 
events in the year prior to recruitment. The average 
patient entered the model aged 71.3 and with a virtual 
CHADS2 score of 2.94. The distribution of CHADS2 stroke 
risk scores also matched the REVEAL AF trial population 
(see online supplementary file 2).
Probabilities
Event probabilities used in the model are shown in 
table 1. Values were derived from published studies of 
baseline risks and calculated via drug treatment effects 
applied on those risks (see online supplementary file 3).
AF incidence, detection and subsequent treatment
The model definition of AF corresponded to that used 
in the REVEAL AF trial.5 Base-case AF episodes were 
defined as lasting for ≥6 min, while a scenario analysis 
explored the impact of AF episodes lasting for ≥5.5 hours 
(see online supplementary file 2). AF detection rates for 
patients receiving an ICM (Reveal®, Medtronic) were 
modelled based on the first 30 months of observations 
from the REVEAL AF trial (figure 2). Beyond month 30, 
a constant long-term AF risk of 3.9% per cycle was derived 
based on average detection rates across the REVEAL AF 
study (excluding the first 3 months). Because ICMs may 
fail to identify some episodes of AF, the calculation of AF 
incidence incorporated an assumed device sensitivity of 
96.1%.8
The analysis assumed that on AF detection, all patients 
were administered NOAC therapy, in accordance with 
National Institute for Health and Care Excellence (NICE) 
guidance.9 In a scenario analysis, a lower NOAC uptake 
(66.35%) was assumed, based on an average of NOAC 
uptake from published sources.5 10
Ischaemic stroke risk and severity
In each cycle, the risk of having an ischaemic stroke (IS) 
was based on patients’ AF status, virtual CHADS2 score, 
anticoagulation treatment and age (see table 2). IS 
risk calculation involved synthesis from several publica-
tions.1 11–13 IS severity was assigned to a distribution based 
on published cost-effectiveness analyses14 15; this distribu-
tion was independent of anticoagulation treatment status 
(see online supplementary file 4). The probabilities for 
events and severity are summarised in table 2.
Bleeding events and anticoagulation therapy changes
Bleed risks were assumed to be related to NOAC treat-
ment and age. The type and likelihood of bleeds were 
based on published analyses,14 15 and their severity (see 
online supplementary file 4) was independent of any 
anticoagulation treatment given (see table 1).6 Non-fatal 
extracranial bleeds were assumed to cause temporary 
(6 week) discontinuation of NOACs in 75% of patients 
receiving NOAC and permanent discontinuation in 25% 
of patients receiving NOACs. Among patients on aspirin, 
25% were precluded from receiving NOAC in future 
if they experienced a bleed.16 17 Non-fatal intracranial 
bleeds caused temporary (6 week) discontinuation of 
NOAC therapy in 44% of patients on NOAC, whereas 
56% had their NOAC therapy discontinued permanently 
(or banned from use in future, where the event occurred 
while the patient was on aspirin).16 17 Clinically relevant 
non-major (CRNM) bleed did not lead to discontinuation 
of NOAC. Haemorrhagic strokes while on NOAC therapy 
led to discontinuation and switch to aspirin in 100% of 
cases—or preclusion from receiving NOAC in future if 
the patient was on aspirin. NOACs were not restarted in 
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Figure 1 Model flow. *NOACs are administered in base-case analysis and warfarin is substituted in sensitivity analysis. 
AF, atrial fibrillation; CRNM, clinically relevant non-major; ECH, extracranial haemorrhage; HS, haemorrhagic stroke; ICH, 
intracranial haemorrhage; IS, ischaemic stroke; NOAC, new oral anticoagulants.
patients with haemorrhagic stroke (HS) even if they later 
had a positive AF diagnosis. Finally, 16% of patients on 
NOAC were assumed to discontinue treatment each year 
for reasons unrelated to bleeding events.15
In terms of cost and QoL impact, non-fatal extracra-
nial haemorrhage, other intracranial haemorrhage 
(ie, non-haemorrhagic strokes) and CRNM bleeds had 
temporary consequences applied to the cycle in which 
the bleed occurred. By contrast, IS and HS were assumed 
to have permanent consequences for ongoing costs, 
QoL and long-term mortality risk, with different levels of 
impact depending on stroke severity (table 1).
Mortality
Age-dependent background mortality in the model was 
based on UK life tables adjusted as required to exclude 
deaths due to cerebrovascular events.18 Following 
non-fatal strokes, mortality risk increased depending on 
stroke severity and treatment (see online supplementary 
file 5).
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Table 1 Annual risks and severity of bleeds and haemorrhagic stroke, by anticoagulant treatment received
No treatment Aspirin NOAC*† Warfarin*
ICH‡ 0.2% 0.5% 0.3% 0.8%
  HS§ 0.1% 0.3% 0.2% 0.5%
  Other ICH 0.1% 0.2% 0.1% 0.3%
ECH¶ 2.0% 2.5% 2.7% 3.1%
  GI bleed 0.8% 1.0% 1.1% 1.3%
  Other ECH 1.2% 1.4% 1.6% 1.8%
All major bleeds 2.2% 2.9% 3.1% 3.8%
CRNM bleed 5.3% 6.9% 7.9% 9.5%
HS severity Mild: 28%; moderate: 23%; severe: 12% fatal: 37%14 15
Case fatalities Due to other ICH: 13%, due to ECH: 2%14 15
*NOAC was used as treatment in base-case analysis and warfarin was considered in sensitivity analysis.
†A class effect was assumed by taking the average across apixaban, dabigatran (low and high dose), rivaroxaban, edoxaban (low and high 
dose).11
‡ICHs (59.7%) were assumed to be HS.14 15
§HS risk was adjusted by a factor of 1.97 (95% CI 1.79 to 2.16) per decade.31
¶ECHs (41.8%) were assumed to be GI bleeds.14 15
CRNM, clinically relevant non-major; ECH, extracranial haemorrhage; GI, gastrointestinal; HS, haemorrhagic stroke; ICH, extracranial 
haemorrhage; NOAC, new oral anticoagulant.
Figure 2 AF detection rates in REVEAL AF—all patients. AF, 
atrial fibrillation; ICM, insertable cardiac monitor.
Health-related QOL
Baseline EuroQol-five dimension data came from the 
REVEAL AF study. Utility data for health states and acute 
events were adapted from a similar analysis in patients 
with cryptogenic stroke,6 adjusting for the absence of 
stroke history in majority of patients.14 15 19 20 Modelled 
utilities are presented in table 3 and further detailed in 
the online supplementary file 6.
Resource use and costs
ICM device costs
The model accounted for one-time costs associated with 
inserting the ICM and subsequently removing it after 
battery expiry (assumed 3 years after insertion). Per 
cycle, costs were applied for ICM patients to cover visiting 
a healthcare professional if AF was detected, as well as 
regular ICM diagnostics, interrogation and unsched-
uled device-related visits. Unscheduled visit frequency 
was based on rates in the REVEAL AF trial. Patients 
with undetected AF continued SoC after their ICM was 
removed. There was also a risk (2.9%) of unplanned ICM 
removal before 3 years due to a range of clinical, tech-
nical or personal factors (Medtronic data on file).
Other costs
OAC treatment costs were estimated as an average of all 
European Medicines Agency (EMA) licensed NOACs: 
apixaban, dabigatran, edoxaban and rivaroxaban (see 
online supplementary file 7).
Acute events, such as strokes and bleeds, were associ-
ated with high short-term costs. When they resulted in 
permanent health consequences, ongoing costs were 
attached to being in a ‘post-stroke’ health state. Health 
state and event costs are summarised in table 3.
SoC costs and diagnostic yield assumptions
The REVEAL AF study did not contain information about 
SoC monitoring costs and diagnostic yield. We assumed 
that patients whose AF risk matched the REVEAL AF 
trial could be reasonably expected to receive a 24 hours 
Holter monitor once per year. Holter monitor costs were 
assumed to be captured by the UK NHS reference cost 
for ECG monitoring and stress testing.21
Relative diagnostic yield of ICM versus SoC was defined 
by an estimated HR of 33.9 (95% CI 13.2 to NE), based on 
a comparison of AF monitoring strategies in patients at 
high risk of AF and stroke, using REVEAL AF clinical trial 
data.22 After ICM explantation, we assumed that patients 
would be followed up and detected with AF according to 
SoC-specific risks.
Analyses
An incremental cost-effectiveness ratio (ICER) was 
calculated for ICM versus SoC, considering QALYs and 
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Table 2 Annual stroke risk and severity by CHADS2 risk score, AF status and anticoagulant treatment received
CHADS2 score
No AF AF
No treatment Aspirin No treatment Aspirin NOAC*† Warfarin*
0 0.2% 0.2% 1.1% 0.8% 0.3% 0.3%
1 0.6% 0.5% 3.1% 2.2% 0.8% 0.8%
2 1.3% 0.9% 6.3% 4.5% 1.7% 1.7%
3 2.5% 1.8% 12.0% 8.6% 3.3% 3.2%
4 3.2% 2.3% 15.3% 10.9% 4.2% 4.1%
5 3.6% 2.6% 17.2% 12.3% 4.7% 4.6%
6 4.0% 2.9% 19.2% 13.7% 5.3% 5.1%
IS severity Mild: 42%; moderate: 26%; severe: 10%; fatal: 22%
*NOAC was used as treatment in base-case analysis and warfarin was considered in sensitivity analysis.
†A class-effect for NOAC was assumed by taking the average efficacy of apixaban, dabigatran (low and high dose), rivaroxaban, edoxaban 
(low and high dose).11
‡IS risk was adjusted by a factor of 1.46 (95% CI 0.8 to 2.16) per decade.13
AF, atrial fibrillation; IS, ischaemic stroke; NOAC, new oral anticoagulant.
healthcare costs accumulated over the cohort lifetime. 
Willingness-to-pay thresholds of £20 000 and £30 000 per 
QALY gained were considered.7 Deterministic one-way 
sensitivity analyses were performed on all model param-
eters including baseline characteristics, diagnostic accu-
racy, treatment efficacy and safety, utility and cost values. 
A scenario where warfarin was given instead of NOACs 
was analysed, and treatment discontinuation probabil-
ities were studied in separate analyses. A probabilistic 
sensitivity analysis was performed (1000 samples) with 
appropriate distributions fitted to model values.
Results
Base-case analysis
The base-case deterministic analysis found that ICM 
provided a benefit over SoC of 0.1994 QALYs at an incre-
mental cost of £1424 across patient lifetime and led to 
4.8 fewer strokes per 100 patients (table 4). The base-case 
ICER for ICM versus SoC was £7140 per QALY gained, 
suggesting ICM is a cost-effective intervention for use in 
the UK NHS. The number of ICMs needed to prevent 
one stroke was 21 and to cause a major bleed was 37.
Incremental benefits and costs were estimated for 3 
years of ICM monitoring. ICM monitoring had higher 
initial costs compared with SoC; it was also associated 
with slightly higher health state and bleed-related costs. 
However, by reducing the rates of IS events, use of ICMs 
generated cost-savings both from IS event costs as well as 
post-stroke health state costs (total stroke-related costs 
for ICM were £3783 versus £4270 for SoC).
The probabilistic sensitivity analysis showed that 
differences in the costs and benefits between strategies 
were statistically significant (table 4). The ICM strategy 
had a 77.4% probability of being more cost-effective at 
a threshold of £20 000 per QALY gained; that figure 
rose to 86.4% at a threshold of £30 000. The associated 
cost-effectiveness acceptability curve is presented in the 
online supplementary file 8.
subgroup analysis
The base-case analysis modelled a distribution of CHADS2 
scores matching the REVEAL AF study population, with 
an average value of 2.94.5
The table 5 shows total costs, QALYs and ICER for 
SoC and ICM calculated separately by CHADS2 score 
subgroups. When the analysis was carried out only in 
patients with a CHADS2 score of 2, the ICER for ICM 
versus SoC was higher compared with the base-case anal-
ysis. In patients with a CHADS2 score of 3, the ICER was 
closer to the base-case analysis because CHADS2=3 was 
similar to the average in the base-case analysis. In patients 
with higher risk CHADS2 scores (range 4–6), the ICER 
was higher than in the base-case. This increase can be 
attributed to the lower AF detection rates observed in 
the REVEAL AF trial for the CHADS2=3–4 subgroup 
compared with the all-patients population (base-case).
scenario analysis
The table 5 also shows results for several scenarios that 
were deemed clinically relevant, as they addressed 
essential model assumptions and data inputs. When the 
assumed NOAC given after AF detection was substituted 
with warfarin, the ICER increased slightly. This was driven 
by an increase in costs and a decrease in total QALYs in 
the ICM group, both caused by the higher bleed risks of 
warfarin. The higher costs associated with adverse events 
on warfarin eclipsed any potential cost-saving brought 
by the lower drug acquisition cost (£5.71 per cycle for 
warfarin vs £159.43 for NOAC). In the scenario where 
OAC treatment discontinuation was only allowed in cases 
of bleeding (ie, patients were not allowed to discontinue 
for other reasons), the ICER improved, in large part due 
to the continued protection afforded against IS for a 
greater proportion of the population. Other parameters 
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Table 3 Cost and utilities of interventions, events and health states
Event, intervention or health state
Mean cost 
(£) SE (£) Mean utility SE Source
Stroke and bleed events* 
  Mild IS 3783 997 0.730 0.014 Luengo-Fernandez et al 
(2013a,b) 19 20†  Moderate IS 19 737 2451 0.500 0.037
  Severe IS 26 957 3947 0.130 0.057
  Fatal IS 3403 551 0.000 –
  Mild HS 11 016 2017 0.730 0.014
  Moderate HS 28 301 5563 0.500 0.037
  Severe HS 47 872 12 911 0.130 0.057
  Fatal HS 1771 667 0.000 –
  Disutility for all recurrent (secondary) stroke events (acute 
period)
– −0.150 0.039 Luengo-Fernandez et al 
(2013a)19
Other events
  Other ICH 2880 440 0.700 0.093 Luengo-Fernandez et al 
(2013a,b) and Department of 
Health (2017)19–21
  Cost and disutility of CRNM 473 70 −0.058 0.017
  Cost and disutility of GI bleed 856 70 −0.151 0.040
  Cost and disutility of other ECH 2118 117 −0.151 0.040
  Infection (related to ICM) 757 297 – Department of Health (2017)21
Health states before any event
  Starting utility and No-AF – 0.820 0.008 Data on file, Medtronic 2018
  Disutility for presence of AF – −0.014 0.019 Luengo-Fernandez et al 
(2013a)19
Post-stroke health states (per cycle)
  Postmild stroke (IS or HS) 594 452 0.727 0.012 Luengo-Fernandez et al 
(2013a,b)19 20‡  Post-moderate stroke (IS or HS) 1158 1007 0.582 0.035
  Post-severe stroke (IS or HS) 1759 0.397 0.065
  Disutility for recurrent (secondary) stroke (post-acute period) – −0.068 0.024 Luengo-Fernandez et al 
(2013a,b)19 20
One-time intervention costs
  ICM acquisition and insertion 1426 1129 – Department of Health (2017)21
  ICM removal 757 297 – Department of Health (2017)21
Monitoring and follow-up (per cycle)
  ICM 26.75 – Department of Health (2017)21
  24 hours Holter monitoring 37.88 – Department of Health 
(2013)32†
Drug costs (per cycle)
  Aspirin 6.02 – MIMS (2018)33
  Warfarin 5.71 – MIMS (2018)33
  Warfarin INR monitoring 66.60 – Dorian et al (2014)14 and Lip 
et al (2014)15§
  NOAC* 159.43 – MIMS (2018)33
*NOAC drug cost was assumed to be the average of dabigatran, rivaroxaban, apixaban, and edoxaban
†Unit costs were inflated from 2013 to 2016/2017 values.
‡Unit costs were inflated from 2008/2009 to 2016/2017 values.
§Unit costs were inflated from 2014 to 2016/2017.
AF, atrial fibrillation; ECH, extracranial haemorrhage; GI, gastrointestinal; HS, haemorrhagic stroke; ICH, intracranial haemorrhage; ICM, 
insertable cardiac monitor; INR, international normalised ratio;IS, ischaemic stroke; NOAC, new oral anticoagulant; SoC, standard of 
care.
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Table 4 Base-case results
SoC ICM Difference
Deterministic analysis
  Total costs £11 936 £13 360 £1424
  Total IS per 100 patients 42.38 37.55 −4.83
  QALYs 6.304 6.503 0.199
  Life years 8.825 9.074 0.249
Probabilistic sensitivity analysis (average 95% CrI)
  Total costs £12 229
(£9720 to £15 087)
£14 415
(£10 945 to £20 350)
£2186
(£1225 to £5263)
  Total IS per 100 patients 41.71 (32.11 to 48.75) 37.43 (31.46 to 43.73) −4.29 (−5.03 to −0.65)
  QALYs 6.314 (5.957 to 6.718) 6.491 (6.172 to 6.814) 0.177 (0.095 to 0.215)
  Life years 8.852 (8.422 to 9.330) 9.073 (8.718 to 9.407) 0.221 (0.077 to 0.295)
CrI, credible interval; ICM, insertable cardiac monitor; IS, ischaemic stroke; QALYs, quality-adjusted life years; SoC, standard of care.
Table 5 Sub-group analysis by CHADS2 score and scenario analyses
Scenario description
Total Costs Total QALYs ICER
SoC ICM SoC ICM
ICM versus 
SoC
Base-case analysis £11 936 £13 360 6.304 6.503 £7140
Subgroup analyses* 
CHADS2 score 2 £10 654 £12 332 7.508 7.665 £10 735
CHADS2 score 3 £12 130 £13 591 5.960 6.133 £8425
CHADS2 score 4, 5 and 6 £11 629 £13 070 5.375 5.527 £9463
Scenario analyses
Choice of OAC=warfarin £11 896 £12 971 6.298 6.434 £7900
Treatment discontinuation for reasons other than bleeding=0% £11 959 £13 570 6.316 6.680 £4427
HR ICM vs SoC (diagnostic yield)=8.7834 £11 836 £13 330 6.348 6.518 £8793
Monitoring costs for SoC=assume pulse check and HR of ICM versus 
SoC=1/24th of the Holter monitoring (scenario proposed by clinical experts)
£10 639 £12 808 6.287 6.497 £10 323
Monitoring costs for SoC=assume pulse check and base-case HR of ICM vs 
SoC=33.9
£10 643 £12 811 6.304 6.503 £10 874
AF episode duration lasting for≥5.5 hours† £10 015 £11 737 6.644 6.741 £17 693
OAC uptake after AF diagnosis = 66.35%5 10 £11 923 £13 516 6.302 6.445 £11 145
Time horizon=3 years £2257 £4142 2.219 2.232 £139 742
Time horizon=5 years £3966 £5669 3.294 3.331 £45 916
Time horizon=10 years £7969 £9363 5.136 5.247 £12 512
Time horizon=25 years £11 923 £13 345 6.301 6.500 £7146
*Each CHADS2 subgroup will differ on ischaemic stroke risk, diagnostic accuracy of monitoring strategies, as well as the corresponding 
age and gender mix of the group in the REVEAL AF trial.
†Analyses using the alternative definition of AF episode were carried out using the REVEAL AF clinical data set (data on file, Medtronic 
2018).
AF, atrial fibrillation; ICER, incremental cost-effectiveness ratio; ICM, insertable cardiac monitor; OAC, oral anticoagulation; QALY, 
quality-adjusted life-year; SoC, standard of care.
having a notable effect on the ICER (changes of greater 
than £5000/QALY in its value) included: only registering 
AF diagnosis for episodes lasting 5.5 hours or more; short-
ening the model time horizon to 10 years; shortening the 
model time horizon to 3 years (exceeded £30 000/QALY 
in this last scenario).
A two-way sensitivity analysis simultaneously decreasing 
the HR of AF detection between the ICM and SoC arms 
and the assumed cost of monitoring for the SoC arm 
showed that even when assuming a HR value that is 10% 
of the base case (HR=3.39) and no diagnostic cost for the 
SoC arm, Reveal® is still cost-effective, with an ICER value 
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Figure 3 Tornado diagram. Note: red bars reflect the 
incremental cost-effectiveness ratio impact of the low limit 
of the parameter intervals considered, while blue bars reflect 
the impact of the high limit value of the parameter intervals.
of £18 574 per QALY gained (see online supplementary 
file 8).
sensitivity analysis
Model sensitivity was tested by varying each parameter and 
recording the resulting ICERs. The results of these anal-
yses are summarised in the tornado diagram in figure 3, 
which shows the top 10 most sensitive parameters. One of 
the most sensitive parameters was, as expected, the cost 
of the Reveal® device and implantation procedure, which 
increased the ICER to over £20 000/QALY when using the 
upper limit of the parameter. The model is also sensitive to 
baseline population characteristics, such as age, antiplatelet 
use and prior stroke history, although to a lesser degree. 
Other cost assumptions, such as cost of ICM device explan-
tation, or cost of stroke and post-stroke health states, had 
a significant impact on the model results. The remaining 
scenarios had a smaller impact on the ICER (±£2000/
QALY variation around the base-case value), maintaining 
results well within the willingness to pay threshold.
dIsCussIOn
Overview
Our analyses found that continuous cardiac monitoring 
using ICM in a high-risk population at risk of, but without 
AF was a cost-effective use of resources in the UK NHS 
setting, with the base-case ICER and all but one of the 
sensitivity analysis ICERs falling below the threshold used 
by NICE. The ICER for ICM in this model appeared 
lower than ICERs estimated for ICM in patients with cryp-
togenic stroke6 or unexplained syncope.23
sensitivity—duration of AF
The base-case model assumed that detecting an 
episode of AF at least 6 min in duration would warrant 
the commencement of anticoagulation therapy. The 
frequency and duration of AF can differ from patient to 
patient,24 and if we accept the stasis-based causal mech-
anism between AF and stroke,2 then there is merit in 
discussing how much AF, and how often, is enough to 
warrant anticoagulation.
Although multiple factors are known to be predictive of 
stroke in addition to the duration and frequency of AF,25 
our model assumption for a 6 min AF duration threshold 
is generally supported by findings from other trials and 
UK expert opinion,26–30 if one takes into account differ-
ences in the patient risk profiles, clinical histories and 
management strategies in those trials.
One of our scenario analyses assumed that only 
patients with AF lasting longer than 5.5 hours (a figure 
based on the TRENDS study26 had increased stroke risk 
and received anticoagulation; this scenario produced an 
ICER which was higher than base case but still well below 
the NICE threshold (table 5).
Anticoagulation therapy following AF diagnosis
The cost-effectiveness of a diagnostic strategy depends 
not only on its accuracy and cost but also the costs and 
benefits of timely and accurate diagnosis, which in this 
case derived from receipt of appropriate treatment. Two 
scenario analyses illustrated how the cost-effectiveness of 
ICM monitoring is sensitive to assumptions around the 
proportion who take up and the proportion who persist 
with appropriate treatment following AF detection. The 
base-case model reflects the NICE Clinical Guideline for 
Management of AF (CG180)9 in assuming all patients 
at high risk of stroke in whom AF is detected will start 
on OAC. However, in REVEAL AF, and the comparable 
study PREDATE AF,10 one-third of patients remained on 
only antiplatelet therapy even after AF diagnosis. Under 
this assumption, the ICER increased to £11 145/QALY 
but remained well below the cost-effectiveness threshold. 
The base case also assumed that 16% of patients, beyond 
those who discontinued due to major bleeding, would 
stop treatment each year. If adherence is improved, ICM 
monitoring becomes even more cost-effective.
standard monitoring—use of Holter monitors
Our model assumed the current SoC to be a single 24 
hours Holter monitor administered annually. By contrast, 
the NICE Clinical Guideline for AF management recom-
mends only an opportunistic pulse check for these at-risk 
patients. However, current clinical practice for high-risk 
patients is likely to fall somewhere between opportunistic 
pulse checks and an annual 24 hours Holter. Our scenario 
analyses show that ICM is likely to represent better value 
to the NHS than either strategy.
COnClusIOns
This analysis shows that the use of an ICM is likely to be a 
cost-effective means of detecting incident AF and identi-
fying candidates for oral anticoagulation, with the aim of 
preventing IS. This cost-effectiveness would apply in the 
UK setting as well as other healthcare systems that fund 
interventions based on clinical evidence and comparative 
cost-effectiveness.
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Arrhythmias and sudden death
Currently, ongoing research may provide clearer inputs 
for some of our modelling assumptions, but based on 
the sensitivity analyses we have conducted, the overall 
conclusion with respect to cost-effectiveness is unlikely to 
change.
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